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Abstract 
Rhabdomyolysis associated with fenofibrate monotherapy is extremely rare. Here, we 
report a rare case of rhabdomyolysis of the psoas muscle in an 82-year-old man with 
chronic myelogenous leukemia (CML). He was prescribed fenofibrate because of a 
hypertriglyceridemia. The patient reported generalized muscle pain and right abdominal 
pain while receiving fenofibrate monotherapy. An abdominal computed tomography 
scan and an abdominal ultrasound showed a large and low attenuation and high 
echogenicity, respectively, in the right middle abdominal area. Laboratory values 
included a serum creatine concentration of 4.1 mg/dl and a creatinine phosphokinase 
concentration of 5,882 IU/l. During laparotomy, a large hematoma and necrotic mass was 
identified in the right psoas muscle. Histological examination revealed that the resected 
specimens were of the psoas muscle with irregular fiber sizes, degenerating fibers 
surrounding the inflammatory reaction, and fiber necrosis that is typical for polymyositis. 
Based on these findings and the clinical history, a diagnosis of fenofibrate-induced 
rhabdomyolysis was made. To the best of our knowledge, no patient has ever been 
diagnosed with fulminant psoas rhabdomyolysis due to a fenofibrate monotherapy. This Case Rep Gastroenterol 2011;5:492–496 
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report details the rare case of rhabdomyolysis in a patient with CML associated with 
fenofibrate monotherapy and offers a review of the literature. 
Introduction 
Fibric acid agents have long shown their benefit in the treatment of hyperlipidemia. 
Fenofibrate is effective in reducing serum LDL cholesterol and triglyceride 
concentrations. It is frequently used alone or in combination with statins to treat diabetic 
dyslipidemia and hypertriglyceridemia. The most important side effect of fibrates is 
rhabdomyolysis. Statins are also associated with rhabdomyolysis, and perhaps this raises 
concerns about possible adverse drug interactions. Rhabdomyolysis is a clinical and 
biochemical syndrome that results from skeletal muscle injury and involves the 
subsequent release of muscle cell constituents into the circulation. The typical clinical 
presentation includes muscle weakness, myalgias and dark-colored urine due to 
myoglobinuria, and the diagnosis is usually based on elevated serum skeletal muscle 
enzyme levels [1]. 
Rhabdomyolysis associated with fenofibrate monotherapy is extremely rare and may 
result in myoglobinuria with acute renal failure. Fenofibrate monotherapy is associated 
with the potentially fatal side effect of rhabdomyolysis, which induces acute renal failure. 
We report a rare case of fulminant rhabdomyolysis of the psoas muscle with fenofibrate 
monotherapy in an 82-year-old man with chronic myelogenous leukemia (CML). To the 
best of our knowledge, there are no reports of fenofibrate monotherapy leading to 
fulminant psoas rhabdomyolysis in a patient with CML. We report this rare case and 
review the related literature. 
Case Report 
The patient was an 82-year-old man in the chronic phase of CML who also had 
hypertriglyceridemia. His past medical history was significant for imatinib mesylate (Gleevec
TM) 
treatment 400 mg daily for 4 years since his initial presentation. He had tolerated the medication well 
and achieved a complete cytogenetic remission. Then imatinib was stopped because of liver dysfunction. 
Six months later, he was started on 100 mg of fenofibrate daily, 4 months before presentation, to treat 
hypertriglyceridemia (serum triglycerides: 380 mg/dl). Before the initiation of fenofibrate therapy, the 
patient’s serum creatinine was 1.3 mg/dl and the thyroid-stimulating hormone concentration and liver 
function were within normal limits. Past medical history contained the following pertinent negatives: no 
recent viral illness, history of trauma, or epilepsy, and the absence of any other medications that could 
potentially be associated with rhabdomyolysis. 
Upon admission, the patient had generalized muscle pain and right abdominal pain and the 
following laboratory values: white blood cell count, 186,400/μl; aspartate aminotransferase (AST), 
1,677 U/l; alanine aminotransferase (ALT), 619 U/l; LDH, 3,380 U/l; triglycerides, 234 mg/dl; total 
cholesterol, 117 mg/dl; myoglobin, 990 μg/ml; creatine, 4.1 mg/dl; and creatinine phosphokinase (CPK), 
5,882 IU/l. The red blood cell and platelet counts were within normal limits. The elevated CPK was not 
cardiac in origin because both electrocardiography and myocardial enzyme markers were within normal 
limits. An abdominal computed tomography (CT) scan and ultrasonography showed a large and low 
attenuation and high echogenicity, respectively, in the right middle retroperitoneal area (fig. 1a). No 
calcification was observed in the psoas muscle (fig. 1b). During a subsequent laparotomy, a large 
hematoma and necrotic mass was found in the right psoas muscle (fig. 2a, b). Histological examination 
of the resected specimens revealed a psoas muscle with disproportionate fiber sizes and degenerating 
fibers surrounding the inflammatory reaction. These findings, along with the clinical history, confirmed Case Rep Gastroenterol 2011;5:492–496 
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a diagnosis of fenofibrate-induced rhabdomyolysis (fig. 3a: ×40, b: ×200). The patient died 3 days after 
the operation due to acute renal failure. 
Discussion 
Fibric acid agents have long shown their benefit in the treatment of hyperlipidemia. 
Fenofibrate is effective in reducing serum LDL cholesterol and triglyceride concentrations 
[2, 3]. It has been shown to increase the serum concentration of HDL cholesterol and 
reduce the serum concentration of dense LDL cholesterol. Fenofibrate in combination 
with statins is being used more frequently for the treatment of combined hyperlipidemia 
and to lower non-HDL cholesterol. Statins are also associated with rhabdomyolysis, and 
perhaps this raises concerns about possible adverse drug interactions. The side effects of 
fibrate treatment include gastrointestinal complaints, gallstones, and skin reactions, all 
of which are tolerable and reversible. The most important side effect of fibrates is 
rhabdomyolysis [4, 5]. All fibrates, either as monotherapy or in combination with statins 
or other agents, are associated with rhabdomyolysis. Gemfibrozil had the highest reported 
rates of rhabdomyolysis, followed by bezafibrate, fenofibrate, ciprofibrate, and clofibrate 
[6]. Fibrates are most commonly combined with cerivastatin [6]. Rhabdomyolysis 
associated with fenofibrate monotherapy is extremely rare. The clinical manifestations of 
rhabdomyolysis associated with fibrates are nonspecific. This condition presents as 
myalgias, weakness, fatigue, and dark-colored urine, which usually develop within a few 
days of starting the treatment. Rhabdomyolysis associated with fibrates appears 3 weeks 
to 3 months after the initiation of the medication [5]. The mechanism of rhabdomyolysis 
associated with fibrate therapy remains unclear. It has been suggested that fibrates cause a 
cell-specific injury to human embryonal rhabdomyosarcoma cells in vitro via the 
activation of the nuclear receptor peroxisome proliferator-activated receptor-alpha, 
through which the lipid-lowering action of fibrates is facilitated [7]. It was hypothesized 
that fibrates only exacerbate latent preexisting mitochondrial myopathies or accelerate the 
normal physiologic changes in skeletal muscle [8]. We have reported a case of fulminant 
rhabdomyolysis of the psoas muscle in an 82-year-old man with chronic myelogenous 
leukemia (CML). The rhabdomyolysis of the psoas iliac muscle was detected using 
Tc-99m HMDP bone scintigraphy [9]. A case of fulminant rhabdomyolysis of the psoas 
muscle, which needed an operation, has not previously been reported. 
Myalgias and muscle complaints are common side effects in patients who take imatinib 
for CML [10]. Elevations of CPK are described in only 0.1–1% of patients, according to 
the manufacturer’s labeling. Cases of muscle edema and rhabdomyolysis have rarely been 
reported [11, 12]. These are the etiologic mechanisms of imatinib-induced CPK elevation, 
and occur early in the course of treatment [13]. The elevated CPK levels normalized 
within a few weeks after stopping imatinib [10]. The patient in the current report had 
tolerated the medication well and was in complete cytogenetic remission. Imatinib was 
stopped because of liver dysfunction 6 months before the presentation of rhabdomyolysis. 
Oliguric or nonoliguric acute renal failure is the most common complication of 
rhabdomyolysis, occurring in 10–40% of patients [14]. Acute renal failure secondary to 
fenofibrate monotherapy-induced rhabdomyolysis is rare [15]. 
The current report describes a rare case of rhabdomyolysis in a patient with CML 
associated with fenofibrate monotherapy. Fenofibrate monotherapy is associated with the 
potentially fatal side effect of rhabdomyolysis, which induces acute renal failure. To the Case Rep Gastroenterol 2011;5:492–496 
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best of our knowledge, this is the first report of fenofibrate monotherapy resulting in 
fulminant rhabdomyolysis of the psoas muscle. 
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Fig. 1. a An abdominal CT scan showing a large area of low attenuation in the psoas muscle (arrows). 
b The iliacus muscle was slightly edematous. No calcification was observed in either the psoas muscle or 
the iliacus muscle (arrow). 
 
 
 
Fig. 2. a, b During laparotomy, a large hematoma and necrotic mass was found in the right psoas 
muscle (arrow). 
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Fig. 3. Histological examination of the resected specimens revealed a psoas muscle with 
disproportionate fiber sizes and degenerating fibers surrounding an inflammatory reaction; these 
findings confirmed the diagnosis of fenofibrate-induced rhabdomyolysis (HE stain; a ×40; b ×200). 
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